Catalyst Event
Peptron Inc (087010) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
5/29/2026, 12:00:00 AM
The abstract for Peptron's long-acting obesity treatment candidate PT403 was released ahead of its presentation at the ADA 2026 conference, including pilot results from healthy adults; estimated >5% price impact scheduled.
Korean Translation
미국당뇨병학회(ADA) 2026 발표 전 건강한 성인 대상 파일럿 결과를 포함한 PT403 초록이 공개됨에 따라 5% 이상의 주가 영향이 예정됨.
Related Recent Events
LigaChem Biosciences Inc (141080) · Other
Announced that partner company SOTIO Biotech received Orphan Drug Designation (ODD) from the U.S. FDA for SOT106, an ADC for osteosarcoma treatment that utilizes LigaChem's 'ConjuAll' platform technology. This validation of the platform is estimated to have a medium market impact, expected.
6/4/2026, 12:00:00 AM
Chong Kun Dang Pharm Co (185750) · Other
The company's natural new drug for gastritis, 'Zitec', is scheduled to receive conditional reimbursement approval from the Health Insurance Review and Assessment Service's (HIRA) drug evaluation committee on June 4, 2026, provided the company accepts a price below the evaluated amount. Estimated price impact >=5% as this is a critical step for market entry scheduled.
6/4/2026, 12:00:00 AM
ABL Bio Inc (298380) · Other
ABL Bio submitted an amended Investigational New Drug (IND) application to Korea's MFDS for its immuno-oncology candidate ABL503 on 2026-06-04. The amendment expands the ongoing Phase 1 trial to include a new monotherapy cohort and a new combination therapy arm with a PD-1 inhibitor.
6/4/2026, 12:00:00 AM
Peptron Inc (087010) · Other
Eli Lilly exercised an option to expand its collaboration with competitor Camurus for a long-acting drug delivery technology on June 1, 2026, increasing competition for Peptron's SmartDepot platform; estimated >10% price impact expected.
6/2/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Other
Announced a partnership with Chime Biologics for the development and commercialization of a biosimilar for the immunology drug 'Dupixent', a blockbuster drug with estimated global sales of KRW 27 trillion.
6/2/2026, 12:00:00 AM
Hanmi Pharm Co Ltd (128940) · Other
Hanmi Pharm announced a licensing and collaboration agreement with Eli Lilly for its GLP-2 agonist 'Sonefpeglutide' for up to $1.26 billion on June 1, 2026, including a $75 million upfront payment.
6/1/2026, 12:00:00 AM